FDA expands bladder-cancer approval for Anktiva combination
The treatment is now approved for certain adults with high-grade papillary-only disease that has not responded to BCG.
A first approval for a specific disease group
The Food and Drug Administration has expanded the approved use of Anktiva, given with Bacillus Calmette-Guérin, for adults with high-grade papillary-only bladder cancer that has not grown into the bladder muscle and has not responded to BCG treatment.
FDA described the decision as the first approval specifically for patients with BCG-unresponsive, high-grade papillary-only disease. Anktiva, whose generic name is nogapendekin alfa inbakicept-pmln, was already approved with BCG for another form of high-risk non-muscle-invasive bladder cancer involving carcinoma in situ.
Papillary tumors grow from the bladder lining, while carcinoma in situ forms flat patches. Both can be high grade, meaning they carry a greater risk of recurrence or progression than low-grade disease. The new approval concerns a defined patient group rather than bladder cancer generally.
FDA used evidence across related forms
The agency said it considered clinical and laboratory evidence showing that carcinoma in situ and high-grade papillary tumors share important features, can occur together and may be difficult to distinguish under a microscope. That allowed FDA to use evidence supporting the earlier indication when evaluating the papillary-only group.
The earlier approval was supported by a study of 77 adults with carcinoma in situ, some of whom also had papillary tumors. FDA reported that 62 percent achieved a complete response, with 58 percent of responders maintaining it for at least 12 months and 40 percent for at least 24 months.
Those results do not mean every patient in the newly approved group will have the same outcome. Eligibility, tumor characteristics, prior treatment and follow-up all matter. Treatment decisions require an oncology team familiar with the full prescribing information.FDA is also working to finalize guidance on using evidence from studies of carcinoma in situ to support development for BCG-unresponsive, high-grade papillary-only disease. That policy work is separate from the decision for this specific medicine.
Treatment, risks and follow-up
Anktiva and BCG are administered directly into the bladder through a catheter, initially once a week for six weeks. Additional treatment depends on response and may continue for up to 37 months under the approved regimen.
FDA says common side effects and laboratory abnormalities include painful or frequent urination, urgency, blood in the urine, urinary-tract infections, muscle or joint pain, chills, fever, and increased creatinine and potassium levels.
The prescribing information also warns that delaying surgery to remove all or part of the bladder can allow cancer to spread, which can be fatal. FDA says treatment should stop under specified conditions, including persistent disease after a second six-week course, recurrence, progression or unacceptable toxicity.
The approval expands an option where BCG alone has not controlled disease, but it does not replace individualized discussion of surgery, monitoring and other therapies. Patients should use the FDA announcement as a starting point for questions, not as personal medical advice.